Premium
Solar urticaria unresponsive to intravenous immunoglobulins
Author(s) -
LlamasVelasco Mar,
Argila Diego De,
Eguren Cristina,
GarcíaMartin Patricia,
Ibañes Sara,
GarcíaDiez Amaro
Publication year - 2011
Publication title -
photodermatology, photoimmunology and photomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.736
H-Index - 60
eISSN - 1600-0781
pISSN - 0905-4383
DOI - 10.1111/j.1600-0781.2010.00553.x
Subject(s) - medicine , intravenous immunoglobulins , antibody , dermatology , gastroenterology , anesthesia , immunology
The treatment of solar urticaria (SU) can be difficult. Only a few cases of SU have been treated with intravenous immunoglobulins (IVIg) (as monotherapy or combined with phototherapy), with reported fast and durable increase of solar exposure tolerance. A 61‐year‐old female with severe UVB‐ and UVA‐induced SU and a 62‐year‐old female with severe UVA and visible light‐induced SU were both treated with a single course of IVIg (total dose of 2 g/kg), infused over 3 days. Phototest, performed 3 months after the treatment, showed only a slight minimal urticating dose improvement, and both patients reported just a moderate and ‘transient’ subjective improvement. Our patient's poorer response, compared with previous reports, may be due to differences in IVIg's treatment schedules, which are reviewed.